Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRAL: Docetaxel, Pembrolizumab, and IL-12 Gene Therapy in Anthracycline-Refractory TNBC
NCT04095689Phase 2Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2021
- Primary completion
- Jun 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in triple-negative breast cancer (TNBC), sponsored by Houston Methodist Research Institute. Started May 2021; status: terminated.
02
Drugs
tavokinogene telseplasmid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04095689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04095689.